JP7005772B2 - 眼科疾患の処置 - Google Patents

眼科疾患の処置 Download PDF

Info

Publication number
JP7005772B2
JP7005772B2 JP2020536578A JP2020536578A JP7005772B2 JP 7005772 B2 JP7005772 B2 JP 7005772B2 JP 2020536578 A JP2020536578 A JP 2020536578A JP 2020536578 A JP2020536578 A JP 2020536578A JP 7005772 B2 JP7005772 B2 JP 7005772B2
Authority
JP
Japan
Prior art keywords
weeks
antibody
vegf
treatment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020536578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506947A (ja
Inventor
ウェイカート，ロバート・ジェームズ
オズボーン，アーロン
サーニ，ジャヤシュリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2021506947A publication Critical patent/JP2021506947A/ja
Priority to JP2022000341A priority Critical patent/JP7273204B2/ja
Application granted granted Critical
Publication of JP7005772B2 publication Critical patent/JP7005772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020536578A 2018-02-06 2019-02-05 眼科疾患の処置 Active JP7005772B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022000341A JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862627103P 2018-02-06 2018-02-06
US62/627,103 2018-02-06
US201862729333P 2018-09-10 2018-09-10
US62/729,333 2018-09-10
PCT/EP2019/052704 WO2019154776A1 (en) 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000341A Division JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置

Publications (2)

Publication Number Publication Date
JP2021506947A JP2021506947A (ja) 2021-02-22
JP7005772B2 true JP7005772B2 (ja) 2022-02-10

Family

ID=65352014

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020536578A Active JP7005772B2 (ja) 2018-02-06 2019-02-05 眼科疾患の処置
JP2022000341A Active JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置
JP2023073187A Active JP7646727B2 (ja) 2018-02-06 2023-04-27 眼科疾患の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022000341A Active JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置
JP2023073187A Active JP7646727B2 (ja) 2018-02-06 2023-04-27 眼科疾患の処置

Country Status (12)

Country Link
US (2) US20210139576A1 (https=)
EP (1) EP3749359A1 (https=)
JP (3) JP7005772B2 (https=)
KR (3) KR20250166355A (https=)
CN (4) CN111699004A (https=)
AU (3) AU2019219004B2 (https=)
CA (1) CA3088355A1 (https=)
IL (1) IL276383B2 (https=)
MX (1) MX2020007527A (https=)
SG (1) SG11202006712XA (https=)
TW (3) TW202535932A (https=)
WO (1) WO2019154776A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
FI3743091T3 (fi) 2018-01-26 2025-01-03 Univ California Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
EP3873519A1 (en) 2018-10-29 2021-09-08 F. Hoffmann-La Roche AG Antibody formulation
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3145239A1 (en) * 2019-08-06 2021-02-11 Hugh LIN Personalized treatment of ophthalmologic diseases
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
JP7158626B1 (ja) 2020-09-04 2022-10-21 エフ．ホフマン－ラ ロシュ アーゲー Ｖｅｇｆ－ａ及びａｎｇ２に結合する抗体及び使用方法
TW202221027A (zh) * 2020-09-17 2022-06-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｖｅｇｆ和ａｎｇ－２的雙特異性抗原結合分子
JP2024512701A (ja) * 2021-03-30 2024-03-19 アブプロ コーポレーション 抗ａｎｇ２×ｖｅｇｆ多重特異性抗体を用いて脈絡膜新生血管形成を治療するための方法
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
WO2023028004A1 (en) * 2021-08-23 2023-03-02 Avirmax, Inc. Compositions and methods for transgene expression
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527064A (ja) 2012-07-13 2015-09-17 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
JP2016528166A (ja) 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体結合が変更された非対称抗体および使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
KR20260004598A (ko) * 2011-01-13 2026-01-08 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
KR102083700B1 (ko) * 2012-08-21 2020-03-02 옵코 파마슈티칼스, 엘엘씨 리포좀 제제
KR20150063728A (ko) 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
TWI738632B (zh) * 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
PT3230316T (pt) * 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
WO2017197199A1 (en) * 2016-05-13 2017-11-16 Askgene Pharma Inc. Novel angiopoietin 2, vegf dual antagonists
CN109563124A (zh) * 2016-06-17 2019-04-02 豪夫迈·罗氏有限公司 多特异性抗体的纯化

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527064A (ja) 2012-07-13 2015-09-17 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
JP2016528166A (ja) 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体結合が変更された非対称抗体および使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chakravarthy U. et al.， The novel bispecific monoclonal anti-VEGF/anti-Ang2 antibody RG7716 shows promise in wet age-related macular degeneration patients with suboptimal response to prior anti-VEGF monotherapy， Investigative Ophthalmology & Visual Science, 2016 ARVO Annual Meeting Abstract[online](retrieved on 2021 Aug 2)，2016年09月，Vol.57, Issue 12，retrieved from the Internet<URL:https://iovs.arvojournals.org/article.aspx?articleid=2558448>
EMBO Mol Med.，2016年，8，p.1265-1288
Ophthalmology Retina，2017年，1(6)，p.474-485
Study NCT02484690, Clinicaltrials.gov[online](retrieved on 2020 Nov 30)，2018年02月02日，retrieved from the Internet<URL:https://clinicaltrials.gov/ct2/history/NCT02484690?V_15=View#StudyPageTop>
Study NCT02699450，Clinicaltrials.gov[online](retrieved on 2021 Aug 2)，2017年12月21日，retrieved from the Internet<URL:https://clin icaltrials.gov/ct2/history/NCT02699450?V_9=View#StudyPageTop>

Also Published As

Publication number Publication date
IL276383B2 (en) 2024-01-01
JP2025084977A (ja) 2025-06-03
EP3749359A1 (en) 2020-12-16
CN111699004A (zh) 2020-09-22
TW202000700A (zh) 2020-01-01
MX2020007527A (es) 2020-09-09
AU2019219004B2 (en) 2025-06-05
TW202535932A (zh) 2025-09-16
IL276383A (en) 2020-09-30
AU2019219004A1 (en) 2020-07-16
KR20250166355A (ko) 2025-11-27
CN119770646A (zh) 2025-04-08
JP7646727B2 (ja) 2025-03-17
WO2019154776A1 (en) 2019-08-15
TW202419464A (zh) 2024-05-16
US20210139576A1 (en) 2021-05-13
US20230416353A1 (en) 2023-12-28
IL276383B1 (en) 2023-09-01
AU2025220841A1 (en) 2025-09-11
JP2021506947A (ja) 2021-02-22
KR20240093772A (ko) 2024-06-24
CN119733046A (zh) 2025-04-01
SG11202006712XA (en) 2020-08-28
KR20200119274A (ko) 2020-10-19
AU2025220842A1 (en) 2025-09-11
TWI831764B (zh) 2024-02-11
TWI885720B (zh) 2025-06-01
JP2025084976A (ja) 2025-06-03
CN119909169A (zh) 2025-05-02
JP2022046738A (ja) 2022-03-23
CA3088355A1 (en) 2019-08-15
JP2023099094A (ja) 2023-07-11
JP7273204B2 (ja) 2023-05-12

Similar Documents

Publication Publication Date Title
JP7005772B2 (ja) 眼科疾患の処置
TWI881273B (zh) 眼科疾病之個人化治療
JP7852107B2 (ja) 眼科疾患の処置
JP7852108B2 (ja) 眼科疾患の処置
US20260028395A1 (en) Treatment of ophthalmologic diseases
HK40124040A (zh) 眼科疾病的治疗
HK40123799A (zh) 眼科疾病的治疗
HK40119700A (zh) 眼科疾病的个性化治疗
HK40120882A (zh) 眼科疾病的个性化治疗
HK40120883A (zh) 眼科疾病的个性化治疗
HK40065038A (en) Personalized treatment of ophthalmologic diseases
HK40034720A (zh) 眼科疾病的治疗
HK40065038B (zh) 眼科疾病的个性化治疗

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200629

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200730

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220105

R150 Certificate of patent or registration of utility model

Ref document number: 7005772

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153